Highly Parallel AIDS Assays Using A Microfluidic Flow Cell Array Integrated with

使用集成微流体流动池阵列的高度并行 AIDS 检测

• 批准号: 7685581
• 负责人: Bruce Gale
• 金额: $ 10万
• 依托单位: CARTERRA, INC.
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2010-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7685581
• 关键词: Acquired Immunodeficiency Syndrome; Address; Antibodies; Basic Science; Binding; Biological Assay; Biosensor; Cells; Complex; Data; Deposition; Detection; Development; Diagnostic; Epitopes; Equipment; Goals; HIV; HIV vaccine; HIV-1; Human; Human Development; Image; Immune response; Kinetics; Label; Lead; Liquid substance; Location; Marketing; Methods; Microfluidics; Microscopic; Monitor; Patients; Performance; Plasma; Process; Proteins; Proteomics; Public Health; Reaction; Reproducibility; Research; Running; Sampling; Screening procedure; Serum; Solutions; Spottings; Surface; Surface Plasmon Resonance; System; Technology; Time; Vaccinated; Vaccines; Work; base; cost; design; drug development; drug discovery; improved; in vitro Assay; instrument; nonhuman primate; novel; preclinical study; public health relevance; research study; sensor; tool; two-dimensional; viral detection

DESCRIPTION (provided by applicant): The ultimate goal of this project is to develop a multiplex label free platform for high-throughput HIV specific serum antibody detection of patient samples. To help Wasatch Microfludics reach this ultimate goal, this proposal will address the feasibility of performing high throughput label free detection of serum antibodies to a variety of HIV proteins through the application of a novel microfluidic spotting technology to available Surface Plasmon Resonance (SPR) array platforms. Specifically, a microfluidic flow cell array will be adapted for work with "real world" samples such as plasma, serum, and cell lysates. The flow cell array will have 48 channels and address an array of spots designed to support ongoing pre- clinical trials in non-human primates as well as HIV vaccine trials in humans. The development of a low cost, high throughput, multiplex assay to assess the development of humoral immune responses following vaccine administration is essential for comprehensive immunomonitoring. PUBLIC HEALTH RELEVANCE: The successful completion of this proposal will create a dramatic improvement in the ability to conduct multiplex SPR-based assays in drug discovery and proteomic research. On a greater scale, this will lead to improved diagnostic tools and reductions in the cost and time of drug development, by significantly improving the throughput of label free screening.

描述（由申请人提供）：本项目的最终目标是开发一种用于高通量检测患者样本的HIV特异性血清抗体的多重无标记平台。为了帮助Wasatch Microfludics实现这一最终目标，该提案将通过将新型微流体点样技术应用于现有的表面等离子体共振（SPR）阵列平台，来解决对各种HIV蛋白质的血清抗体进行高通量无标记检测的可行性。具体地，微流体流动池阵列将适于与“真实的世界”样品如血浆、血清和细胞裂解物一起工作。流动池阵列将有48个通道，并解决了一系列的斑点，旨在支持正在进行的临床前试验在非人类灵长类动物以及艾滋病毒疫苗试验在人类。开发一种低成本、高通量、多重检测方法来评估疫苗接种后体液免疫应答的发展，对于全面的免疫监测至关重要。公共卫生关系：该提案的成功完成将大大提高在药物发现和蛋白质组学研究中进行基于SPR的多重测定的能力。在更大的范围内，这将导致改进的诊断工具和减少药物开发的成本和时间，通过显着提高无标记筛选的吞吐量。